The “Eleventh Five-Year” major new drug creation special focus on the support of a class of bio-pharmacy Puyou grams listed on the market, marking China's major new drug creation special entry into the harvest.

Since this year, Zhejiang Beida, Jiangsu Hengrui and Xiansheng Pharmaceutical have listed the company's heavy new drugs respectively, while Tasly's Puyouke belongs to the genetic engineering category of biological medicine. This category is still the only one listed on the market this year. Variety.

According to the report from the director of the Department of Science and Technology Education of the Ministry of Health and the director of the National Office for the Implementation of Special Projects for Major New Drug Development, the “Eleventh Five-Year” major new drug creation project has achieved fruitful results. At present, there are 16 varieties in the country that have obtained new drug certificates and 20 varieties. In submitting new drug registration applications, there are more than 10 self-developed new drugs that have undergone clinical trials in developed countries.

He Wei emphasized that during the "12th Five-Year Plan" period, major new drug creation projects will encourage "breakthrough innovation." According to reports, the major new drug creation project has two development goals. The first is to meet the people's livelihood needs, to solve the old people's difficulties in accessing the doctor, and to see the old and expensive problems; second is to realize industrial adjustment, and to contribute to accelerating the layout of the bio-industries of strategic new industries. .